| Bid | 1.96 |
| Market Cap | 87.89M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | -6.11 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 2.06 |
| Volume | 154,257 |
| Avg. Volume (20D) | 189,140 |
| Open | 2.00 |
| Previous Close | 1.98 |
| Day's Range | 1.96 - 2.06 |
| 52-Week Range | 1.81 - 4.93 |
| Beta | undefined |
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgic...
Analyst Forecast
According to 2 analyst ratings, the average rating for HBIO stock is "Strong Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Next Earnings Release
Analysts project revenue of $24.15M, reflecting a -14.22% YoY shrinking and earnings per share of 0.05, making a 25.00% increase YoY.
2 months ago · seekingalpha.com
Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call TranscriptHarvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO ...
